Publikationen, an denen er mitarbeitet Ana Maria Treviño Rodriguez–Casanova (58)

2024

  1. Prospects for Controlling Hepatitis B Globally

    Pathogens, Vol. 13, Núm. 4

2023

  1. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions

    Journal of Clinical Virology, Vol. 167

  2. Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy

    Drug Design, Development and Therapy, Vol. 17, pp. 155-166

  3. HTLV European Research Network 2023: the silent pandemic of HTLV-1 infection

    AIDS Reviews

  4. Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain

    Alimentary Pharmacology and Therapeutics, Vol. 57, Núm. 5, pp. 540-548

  5. Impact of the COVID-19 pandemic on hospital admissions due to viral hepatitis in Spain

    Journal of Clinical Virology, Vol. 167

  6. Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: A nation-wide population study

    Autoimmunity Reviews, Vol. 22, Núm. 6

  7. Predictors of in-hospital mortality in HIV-infected patients with COVID-19

    QJM, Vol. 116, Núm. 1, pp. 57-62

  8. Safety considerations in the management of hepatitis C and HIV co-infection

    Expert Opinion on Drug Safety, Vol. 22, Núm. 5, pp. 363-372

  9. Susceptibility to hepatitis B virus infection in adults living in Spain

    Liver International, Vol. 43, Núm. 5, pp. 1015-1020

  10. The slowdown of new infections by human retroviruses has reached a plateau in Spain

    Journal of Medical Virology, Vol. 95, Núm. 5

  11. Treatment of hepatitis delta and HIV infection

    Liver International, Vol. 43, Núm. S1, pp. 108-115

2022

  1. Is SARS-CoV-2 the only cause of long-COVID?

    AIDS Reviews, Vol. 24, Núm. 4, pp. 183-196

  2. Late presentation of human T-lymphotropic virus type 1 infection in Spain reflects suboptimal testing strategies: on behalf of the Human T-lymphotropic Virus (HTLV) Spanish Network

    International Journal of Infectious Diseases, Vol. 122, pp. 970-975

  3. Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain

    Hepatology International, Vol. 16, Núm. 5, pp. 1161-1169

  4. Oral antivirals for the prevention and treatment of SARS-CoV-2 infection

    AIDS Reviews, Vol. 24, Núm. 1

  5. Pre-Exposure Prophylaxis for viral infections other than HIV

    Infezioni in Medicina, Vol. 30, Núm. 3, pp. 362-371

  6. Ultra-long-acting (XLA) antivirals for chronic viral hepatitis

    International Journal of Infectious Diseases

  7. Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases

    Future Microbiology, Vol. 17, Núm. 11, pp. 887-897

2021

  1. Envisioning a hepatitis delta cure with new antivirals

    Future Microbiology, Vol. 16, Núm. 13, pp. 927-930